



## Cyclerion to Participate at Upcoming September 2020 Investor Conferences

September 4, 2020

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company management will be participating in several upcoming September 2020 investor conferences:

- Citi's 15<sup>th</sup> Annual BioPharma Virtual Conference on September 9<sup>th</sup>
- H.C. Wainwright & Co 22<sup>nd</sup> Annual Global Investment Conference on September 16<sup>th</sup> at 9:30 a.m. ET
- Cantor Virtual Global Healthcare Conference on September 16<sup>th</sup> and a virtual Fireside Chat on September 17<sup>th</sup> at 3:20 p.m. ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21<sup>st</sup> –23<sup>rd</sup> on September 21<sup>st</sup> at 10:50 a.m. ET

A live webcast of the H.C. Wainwright, Cantor, and Oppenheimer presentations can be accessed within the Investors & Media section of the [Cyclerion.com](https://www.cyclerion.com) website. An archived replay of the webcast will be available for approximately 90 days following the presentation.

### About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Lead programs include its vascular-targeted olinciguat in Phase 2 development for sickle cell disease and IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv)

For more information about Cyclerion, please visit <https://www.cyclerion.com/> and follow us on Twitter ([@Cyclerion](https://twitter.com/Cyclerion)) and LinkedIn ([www.linkedin.com/company/cyclerion](https://www.linkedin.com/company/cyclerion)).

### Investors

Carlo Tanzi, Ph.D.  
Kendall Investor Relations  
[ctanzi@kendallir.com](mailto:ctanzi@kendallir.com)



Source: Cyclerion Therapeutics, Inc.